SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is capturing intense market attention as investors weigh its critical role in the AI infrastructure cycle against high expectations, leading to heavy options activity and polarized community debates over whether results are already priced in. Participants are closely monitoring the upcoming earnings for clarity on future demand, sector growth, and management guidance that could impact the broader market trajectory.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is experiencing significant volatility and downward pressure ahead of its upcoming earnings report, with community sentiment split between those viewing the price drop as a "bear trap" or value buying opportunity and others concerned about insider selling and tariff impacts. Investors remain deeply divided on the stock's future, as many weigh the potential for a growth rebound driven by successful brand acquisitions against the risks of sector rotation and institutional manipulation.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit shares are seeing extreme volatility following earnings that topped analyst estimates but provided cautious forward guidance. The community remains sharply divided, with some investors accumulating shares on the dip as a long-term AI-driven growth play, while others fear the firm's business model faces existential disruption from emerging AI automation tools.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors react to bullish CEO commentary regarding positive GPS immunotherapy data, which is being framed as superior to current standards of care. The community is heavily focused on the potential for an imminent short squeeze and clinical milestones, creating a volatile environment as traders monitor institutional buying activity and the upcoming oncology conference presentation.

Micware Co. Ltd. engages in software development services and innovative IT solutions mainly focused on the automotive and mobility sectors. It operates through the following segments: Software Defined Vehicles (SDV), Location-Based Services (LBS), and Others. The SDV segment relates to the development and sale of software systems designed for SDV, including IVI system software and other mobility-enhancing software products, conducted by its Japanese subsidiaries. The LBS segment covers the development and licensing of in-vehicle navigation software systems, and other geographic data-based services for business-to-business customers, mainly serving end users. The Other segment comprises software development services conducted by overseas subsidiaries designed for SDV, and business-to-consumer mobile app services unrelated to in-vehicle navigation. The company was founded by Kenji Narishima in March 2003 and is headquartered in Kobe, Japan.

Micware Co. Ltd. - ADR

Micware is experiencing extreme volatility and heavy retail attention as traders speculate on its potential for a massive rally following a recent IPO. The community is actively debating whether the stock is a legitimate opportunity or a classic pump-and-dump scheme, with many watching for breakout levels while navigating multiple trading halts.

Applied Digital Corporation

Applied Digital is currently trending following a major lease announcement with a high-grade hyperscaler that pushed its contracted AI capacity past the gigawatt threshold, fueling significant community excitement about its long-term growth. Investors are actively discussing the stock's potential for further gains as it continues to expand its data center footprint, with many using the recent price volatility as an opportunity to add to their positions.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp

AEVEX Corp. is drawing significant community interest following its strong debut, fueled by its operational role in defense-tech and autonomous drone systems. Traders are actively debating the company's valuation and growth potential against established peers, with many focused on its substantial backlog and ability to secure key U.S. government contracts in an evolving defense environment.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending following news that the SEC has closed its three-year probe into the token, sparking a significant rally and community discussions regarding its potential to regain past highs. Traders are actively debating whether this movement represents a sustainable breakout or a temporary pump, while many enthusiasts highlight Zcash's privacy features and limited supply as catalysts for long-term growth.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending as investors debate the impact of advanced AI models like Anthropic's Mythos on cybersecurity software, with bullish sentiment focused on the stock's role in the new defensive infrastructure alongside Palo Alto Networks. While some community members worry about potential valuation compression and margin headwinds, others highlight the firm's critical platform expansion and persistent enterprise demand as institutional smart money continues to evaluate the sector's long-term resilience.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics (OPTX) is trending as investors react to its position as a domestic supplier of high-precision optics for defense, space, and AI infrastructure, further bolstered by recent defense purchase orders. The community is actively debating the company's growth potential against its financial positioning, with discussions focused on its role in the U.S. defense supply chain and its ability to scale production for LEO satellite and AR military programs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Vanda noted that in the Gemini-1 and Gemini-2 studies evaluating the efficacy of Imsidolimab, more than half of the patients achieved clear or almost clear skin by the fourth week, compared to 13% on placebo.</li><li>The company said that efficacy was maintained throughout an approximately 2-year maintenance period with monthly doses, and no flares occurred in the active treatment arm.</li><li>Vanda added that GPP is a rare disorder with prevalence estimates varying widely by region, ranging from approximately 2 to 124 cases per million worldwide.</li></ul>Vanda Pharmaceuticals Inc. (VNDA) on Wednesday announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application for Imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP).The company noted that if the FDA approves its application, Imsidolimab could address a significant unmet medical need in this rare and life-threatening disorder.<a href="https://stocktwits.com/symbol/VNDA">Vanda shares</a> were up nearly 5% in Wednesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory at the time of writing.<h2 class="st-heading-2">Vanda Says Over Half Of Patients Achieved Clear Or Almost Clear Skin</h2>Vanda noted that in the Gemini-1 and Gemini-2 studies evaluating the efficacy of Imsidolimab, more than half of the patients achieved clear or almost clear skin by the fourth week, compared to 13% on placebo.The company said that efficacy was maintained throughout an approximately 2-year maintenance period with monthly doses, and no flares occurred in the active treatment arm.Vanda added that GPP is a rare disorder with prevalence estimates varying widely by region, ranging from approximately 2 to 124 cases per million worldwide.“Imsidolimab builds on our growing expertise in rare orphan disorders and our anti-inflammatory portfolio. Imsidolimab represents a precision medicine approach targeting a disorder with a known genetic cause using a fully humanized monoclonal antibody against the IL-36 receptor,” said Vanda CEO Mihael H. Polymeropoulos.<h2 class="st-heading-2">What Does Vanda Do?</h2>Vanda Pharmaceuticals is a Washington-based biopharmaceutical company focused on the development and commercialization of therapies that cater to highly unmet medical needs.Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling. The company expects regulatory and patent exclusivity for the treatment to extend into the late 2030s.<a href="https://stocktwits.com/symbol/VNDA">VNDA stock</a> is down 7% year-to-date, but up 88% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rxrx-stock-soars-pre-market-on-q4-beat-recursion-reached-inflection-point/cZRy27nR46D">RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Vanda Pharmaceuticals Inc. logo is pictured before a regular season Major League Baseball game between the Chicago White Sox and the Detroit Tigers on September 05, 2025. (Photo by Joseph Weiser/Icon Sportswire via Getty Images)

Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder

Vanda Pharma company noted that if the FDA approves its application, Imosidolimab could address a significant unmet medical need in this rare and life-threatening disorder.

Equity

The company noted that if the FDA approves its application, Imosidolimab could address a significant unmet medical need in this rare and life-threatening disorder.

<ul class="summary-bullets"><li>Kelce’s total ownership will remain below 5%.</li><li>The three-time Super Bowl champion will appear in Sleep Number’s national marketing campaigns, including television commercials and digital content across social and online platforms.</li><li>The deal also strengthens the company’s long-standing partnership with the NFL.</li></ul>Shares of Sleep Number Corp. (SNBR) jumped more than 10% after the opening bell on Wednesday after the company announced that Kansas City Chiefs star and three-time Super Bowl champion Travis Kelce became a minority shareholder.As part of the agreement, Kelce will acquire Sleep Number common stock on the open market and receive restricted stock units that vest over the initial three-year term. Kelce’s total ownership will remain below 5%, though he will become one of Sleep Number’s top shareholders.As part of the three-year agreement, Kelce will appear in Sleep Number’s national marketing campaigns, including television commercials and digital content across social and online platforms. President and CEO, Linda Findley, said that Kelce’s presence will be a “helpful accelerator” in a bid to attract new and younger consumers to the brand.The three-year collaboration with Kelce is a central to Sleep Number’s broader marketing strategy and further strengthens its partnership with the National Football League (NFL), which the company has served as an official partner since 2018.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/SNBR">SNBR</a> on Stocktwits shifted to ‘bullish’ from ‘neutral’ a day earlier.<img src="https://news.stocktwits-cdn.com/SNBR_jpg_cff0c4a2b2.webp" alt="SNBR.jpg">One user sees upside potential in the stock.<stembedurl>https://stocktwits.com/Mr__G/message/640636200</stembedurl>Earlier this month, Piper Sandler raised the stock’s price target to $12 from $5 and maintained a ‘Neutral’ rating, according to The Fly.Sleep Number will be hoping that Kelce’s involvement will bring a boost to sales, which fell 19.6% to $343 million in the third quarter, while net loss widened to $40 million.The stock has declined 42% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sbux-stock-climbs-7-premarket-after-q1-results/cmyg421R40I">SBUX Stock Jumps 7% Today – US Transactions Grow For The First Time In Two Years</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tight end Travis Kelce #87 of the Kansas City Chiefs poses on the red carpet upon arrival for "The Kingdom" screening hosted by the Kansas City Chiefs at Kauffman Center for the Performing Arts.

NFL Star Travis Kelce Just Became A Minority Shareholder In This Mattress Company – Stock Gains 10%

Kelce will acquire Sleep Number common stock on the open market and receive restricted stock units that vest over the initial three-year term.

<ul class="summary-bullets"><li>Vanda said it disagrees with the FDA assessment, noting that phase-advance models are widely accepted in circadian rhythm research.</li><li>The company emphasized Tasimelteon’s well-established safety profile.&nbsp;</li><li>The company had recently received FDA approval for NEREUS (Tradipitant), a motion-sickness treatment aimed at preventing vomiting.</li></ul>Shares of Vanda Pharmaceuticals Inc. (VNDA) fell 10% in premarket trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) stated that its supplemental New Drug Application for HETLIOZ (tasimelteon) to treat jet lag disorder cannot be approved in its current form.While the FDA acknowledged positive results from Vanda’s clinical trials, it cited concerns that the controlled phase-advance protocols used in the studies do not fully replicate real-world jet travel conditions, including reduced oxygen pressure, noise, and lighting changes.Vanda said it disagrees with the FDA assessment, noting that phase-advance models are widely accepted in circadian rhythm research and effectively simulate core jet-lag symptoms. The company emphasized tasimelteon’s well-established safety profile and demonstrated benefits on sleep and next-day alertness.This comes after the company received FDA approval for NEREUS (Tradipitant), a motion-sickness treatment aimed at preventing vomiting on December 31, 2025.The FDA approval marked the first new pharmacologic treatment for motion sickness in more than 40 years. Vanda expects to launch NEREUS in the coming months. Beyond motion sickness, Vanda is advancing tradipitant in clinical development for other conditions driven by similar pathways, including gastroparesis and nausea linked to GLP-1 therapies.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday decline, retail sentiment on Stocktwits turned 'bullish' from 'neutral' a day earlier.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/VNDA_jpg_66bd88803d.webp" alt="VNDA.jpg" width="922" height="88"><figcaption>&nbsp;</figcaption></figure>One bullish user sees strong buy at this level, stating that the motion sickness drug approval is a much bigger news than today's update.<stembedurl>https://stocktwits.com/pablo4/message/641232419</stembedurl>Over the past one year, <a href="https://stocktwits.com/symbol/VNDA">VNDA shares</a> have gained around 52%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Vanda Pharmaceuticals Inc. logo is pictured before a regular season Major League Baseball game, on September 05, 2025, at Comerica Park in Detroit, Michigan. 

Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application

The FDA cited concerns that the controlled phase advance protocols used in studies do not fully replicate real-world jet travel conditions.

Aehr Test Systems, Inc. (AEHR) shares fell nearly 17% in Monday’s extended session after the semiconductor testing solutions company reported a year-over-year drop in its first-quarter revenue and failed to issue formal guidance, citing tariff-related uncertainty.On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/AEHR">Aehr Test Systems stock</a> remained ‘bearish’ (35/100) as of late Monday, while the message volume was ‘extremely high.’<figure class="image"><img style="aspect-ratio:615/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_06_at_10_18_25_PM_png_b187da5bec.webp" alt="Screenshot 2025-10-06 at 10.18.25 PM.png" width="615" height="57"><figcaption>AEHR sentiment and message volume as of 10:15 p.m. ET, Oct. 6 | source: Stocktwits</figcaption></figure>The Fremont, California-based company’s revenue for the first quarter of the fiscal year 2026 fell to $11 million from $13.1 million in the year-ago period, although it exceeded the Fiscal.ai-compiled consensus of $10.77 million. The adjusted earnings per share (EPS) were $0.01, down significantly from the year-ago’s $0.07. &nbsp;Analysts, however, were bracing for only break-even results. Bookings totaled $11.4 million for the quarter, and backlog as of Aug. 29 was $15.5 million.&nbsp;President and CEO Gayn Erickson said, “We are pleased with the start to this fiscal year, with revenues across several market segments and momentum in sales and customer engagements in both wafer-level and packaged part test and burn-in of artificial intelligence (AI) processors.” He noted that the company’s lead production customer, a hyperscaler, has multiple follow-on volume production orders for its new Sonoma ultra-high-power packaged part burn-in systems.&nbsp;Looking ahead, Erickson said he expects nearly all of the company’s served markets to see order growth in the fiscal year, with silicon carbide growth expected to strengthen further in the next fiscal.“Although we remain cautious due to ongoing tariff-related uncertainty and are not yet reinstating formal guidance, we are confident in the broad-based growth opportunities ahead across AI and our other markets.”A bearish user lamented the company's cash burn, calling it “brutal.” They noted that free cash flow has been negative for seven out of the last eight quarters and that in the first quarter alone, the company burned $6.8 million. “At this rate, they’ll need to raise cash soon,” they said.<stembedurl>https://stocktwits.com/AnonMav/message/631243851</stembedurl>Another watcher called the company an “overhyped” name that is failing to live up to expectations. They see more room for the stock to fall.<stembedurl>https://stocktwits.com/BIG_BEAR_/message/631242779</stembedurl>For the year-to-date period, Aehr Test System stock has gained over 90%. Wall Street analysts, however, don’t share traders’ optimism. According to Koyfing, the consensus price target for the stock is $16.50, implying nearly 50% downside from Monday’s close.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-says-happy-to-work-with-democrats-on-failed-healthcare-policies/ch62HkbR3gz">Trump Says He's 'Happy To Work' With Democrats On 'Failed' Healthcare Policies, But Calls To End Government Shutdown</a>

In this photo illustration, the AEHR Test Systems logo is displayed on a smartphone screen, on April 6, 2025, in Chongqing, China. 

Why Aehr Test Systems Stock Tumbled Nearly 17% In After-Hours

Looking ahead, CEO Gayn Erickson said he expects nearly all of the company’s served markets to experience order growth in the fiscal year, with silicon carbide growth expected to strengthen further in the next fiscal year.

Verint Systems, Inc. (VRNT), a software-as-a-service (SAAS) company that provides customer experience automation and workforce management solutions, is reportedly close to striking a deal to be bought by private-equity firm Thoma Bravo.Reacting to the rumor,&nbsp;<a href="https://stocktwits.com/symbol/VRNT">Verint Systems' stock</a> jumped over 18% in overnight trading on Sunday.A Bloomberg report, citing people familiar with the matter, stated that the deal valued Verint at approximately $2 billion, including the company’s debt. This compares to the company’s $1.231 valuation as of the stock’s closing price of $20.47 on Friday.The deal could be announced as early as Monday, the report said, adding that talks could fall through or the timing and terms could change.Bloomberg had reported in July that the two companies were in talks regarding a potential deal.&nbsp;Thoma Bravo has been actively pursuing software deals, with the firm striking a $12.3 billion deal to acquire human resources management software firm Dayforce last week.&nbsp;Meanwhile, Verint has been quick to adopt artificial intelligence (AI) to improve operational efficiency. The company announced in late July that it&nbsp;had achieved a 70% reduction in cost per interaction and handled three times the call volume in contact centers by using Verint Bots.The company counts among its customers high-profile firms such as Alphabet’s Google, Microsoft, Analog Devices, FedEx, and Lyft.Verint’s first-quarter results, announced in early July, showed a 6% year-over-year decline in revenue, but both top- and bottom-line results exceeded guidance. The company reaffirmed its guidance for the fiscal year 2026.On Stocktwits, retail sentiment toward Verint stock stayed ‘bearish’ (34/100) late Sunday, with the sour mood accompanied by ‘normal’ volume. The sentiment meter, however, is yet to factor in the deal speculation.&nbsp;<figure class="image"><img style="aspect-ratio:613/52;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_24_at_10_04_43_PM_png_d7304af53d.webp" alt="Screenshot 2025-08-24 at 10.04.43 PM.png" width="613" height="52"><figcaption>VRNT sentiment and message volume as of 10:05 p.m.m Aug 24 | source: Stocktwits</figcaption></figure>Verint shares have declined by over 25% this year, compared to the S&amp;P 500’s 10% gain.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/can-byd-be-china-s-ferrari-ev-giant-opens-race-tracks-for-200-k-cars/chssEcCRdKZ">Can BYD Be China’s Ferrari? EV Giant Opens Race Tracks For $200K Cars</a>

The Verint Systems building located at 330 South Service Road in Melville, New York, on January 6, 2014. 

Thoma Bravo Said To Be Eyeing Verint Takeover In $2B Deal Just Days After Report Of Dayforce Buy

The private-equity firm has been actively pursuing software deals, with the firm striking a $12.3 billion deal to acquire human resources management software firm Dayforce last week. 

The Zacks Analyst Blog Highlights SPY, IWM, QQQS, DEEP, SGDJ and CALF

IWM and other small-cap ETFs are gaining steam as earnings growth picks up and investor sentiment starts to shift.

Are Small Caps Finally Ready to Take the Leap?

IWM gained 4.6% in a month as small caps show signs of life, narrowing the gap with large caps after a long slump. Is this the start of a winning trend or just a short-term rebound?

Aehr Test Systems, Inc. (AEHR) shares fell over 20% in Wednesday’s early premarket session after the small-cap semiconductor testing solutions company announced mixed quarterly results and flagged a potential slowdown in the first quarter due to tariffs.On Stocktwits, retail sentiment toward <a href="https://stocktwits.com/symbol/AEHR">Aehr stock</a> tempered to ‘bullish’ (73/100) by early Wednesday, from the ‘extremely bullish’ stance seen a day ago. The message volume continued to be ‘extremely high.’<figure class="image"><img style="aspect-ratio:620/54;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_09_at_5_29_07_AM_png_a0a66f4b8e.webp" alt="Screenshot 2025-07-09 at 5.29.07 AM.png" width="620" height="54"><figcaption>AEHR sentiment and message volume as of 5:30 a.m. ET, July 9 | source: Stocktwits</figcaption></figure>A bullish watcher suggested they would buy the dip.<stembedurl>https://stocktwits.com/StockWits59/message/620281907</stembedurl>Another user shrugged off the near-term headwinds, expressing confidence over a new hyperscaler customer the company announced.<stembedurl>https://stocktwits.com/KiaNiro/message/620271391</stembedurl>Fremont, California-based Aehr reported an adjusted loss per share of $0.01 for the fourth quarter of the fiscal year 2025, reversing from earnings per share (EPS) of $0.84. The company clarified that the year-ago’s bottom-line results included a tax benefit.The bottom-line result was in line with the Finchat-compiled consensus estimate.Quarterly revenue fell to $14.1 million from $16.6 million in the fourth quarter of 2024, slightly below the $14.82-million consensus estimate.Bookings totaled $11.1 million, and backlog stood at $15.2 million as of May 30.&nbsp;Aehr CEO Gayn Erickson said, “Fiscal 2025 was a transformative year for Aehr Test Systems, marked by significant progress on our strategic initiatives to expand our total addressable market, diversify our customer base, and enhance our product portfolio.”“A major milestone was the successful launch and adoption of our first production wafer-level burn-in (WLBI) system specifically for artificial intelligence (AI) processors."Erickson also disclosed that one of the leading processor companies&nbsp;has requested to proceed with an evaluation for wafer-level testing of one of its current high-volume processors.The executive expressed confidence that nearly all the opportunities and market verticals Aehr serves will experience order growth in fiscal year 2026. However, he warned that the silicon carbide market could see an order decline, as customer forecasts are back-half loaded, with stronger growth expected in fiscal year 2027.Erickson also said tariffs will likely impact performance in the near term. “While we remain confident in Aehr’s long-term growth prospects, we continue to experience some timing-related delays in order placements due to tariff-related uncertainty, particularly in our first quarter,” he said, adding that the company would not reinstate specific guidance beyond what it had already stated.Aehr stock has lost about 9% year-to-date, underperforming the broader market and the tech sector.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dollar-climbs-off-multi-year-lows-as-report-unpacks-bessent-influence-on-tariff-timeline/chFUtg2R5i2">Dollar Climbs Off Multi-Year Lows As Report Unpacks Bessent’s Influence On Trump Tariff Timeline</a>

Aehr Stock Slumps 20% Premarket After CEO Flags Tariff-Induced Order Delays — Retail Clings To Bullish Stance

Quarterly revenue fell to $14.1 million from $16.6 million in the fourth quarter of 2024, slightly below the $14.82-million consensus estimate.

Himax Technologies, Inc. ($HIMX) shares jumped on Thursday after an analyst said the Taiwanese fabless semiconductor company could be a potential wafer-level optics (WLO) supplier for Nvidia Corp. (<a class="mention" data-mention="$NVDA" data-symbol-id="NVDA" href="https://stocktwits.com/symbol/NVDA" target="_blank">$NVDA</a>) and Taiwan Semiconductor Manufacturing Company Ltd. (<a class="mention" data-mention="$TSM" data-symbol-id="TSM" href="https://stocktwits.com/symbol/TSM" target="_blank">$TSM</a>).Himax stock settled Thursday’s session up 44.93% at $9.71 on about 25 times its average volume. This marked its highest close since Jan. 18, 2022.TFI Securities analyst Ming-Chi Kuo said in a post on Medium that he expects Himax to leverage its WFO technology and strong partnership with Fiber Optics Communications to enter the supply chain for TSM’s co-packaged optics (CPO) and Nvidia’s next-generation artificial intelligence (AI) chips Rubin series.&nbsp;Himax has a 5.3% equity stake in Fiber Optics Communications, Kuo said.“Looking ahead, CPO is anticipated to become the critical chip design of AI servers and HPC, making WLO a key driver of long-term growth for Himax,” he added.The analyst expects the demand for WLO technology, driven by CPO applications, to begin contributing to Himax's revenue in the fourth quarter of 2024, primarily driven by technical qualification and trial production. He expects steady growth in 2025 and rapid acceleration in 2026.Later, Baird analyst Tristan Gerra upped the price target for Himax stock from $5 to $7 and maintained an ‘Outperform’ rating, citing CPO and augmented reality (AR) opportunities. These opportunities reach to Himax’s core technological capabilities and represent secular growth vectors, the analyst said.Gerra said Himax is well-positioned to benefit from TSMC’s plan to ramp photonics within CoWoS packaging in 2026 to address AI-driven surging bandwidth demand.Himax is also well-positioned with its microdisplay and waveguide patented technologies into a new class of AR devices launching in the next two to three years as tier-one OEMs have given up on internal microdisplay development efforts, he added.’<figure class="image"><img style="aspect-ratio:635/137;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/himx_sentiment_24f543abad.png" alt="himx_sentiment.png" width="635" height="137"><figcaption>HIMX sentiment and message volume December 12, 2024, as of 10:47 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, sentiment toward Himax improved from ‘neutral’ a day ago to ‘extremely bullish’ (97/100), marking the highest level in over a year. Reflecting increasing activity levels among retailers, message volume spiked to ‘extremely high.’One Stocktwits user said Himax is headed toward $100 in 2025 and was bigger than AI server maker Super Micro Computer, Inc. (<a class="mention" data-mention="$SMCI" data-symbol-id="SMCI" href="https://stocktwits.com/symbol/SMCI" target="_blank">$SMCI</a>).<stembedurl>https://stocktwits.com/Slifka/message/596284172</stembedurl>Following the gain in Thursday’s regular session, the stock pulled back by 4.74% in after-hours trading. The stock is up about 66% for the year-to-date period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Himax Stock Jumps As Analysts Tout Potential Nvidia, TSMC Supply Chain Opportunities: Retail Sentiment Brightens

Co-packaged optics is anticipated to become the critical chip design of AI servers and HPC, making WLO a key driver of long-term growth for Himax, said an analyst.

QQQS
Invesco NASDAQ Future Gen 200 ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest QQQS News

QQQSInvesco NASDAQ Future Gen 200 ETF